Bleb injections ward off orbital tumours
Bleb injections of subconjunctival chemotherapy lower the risk of developing orbital tumours in patients with retinoblastoma.
Bleb injections of subconjunctival chemotherapy lower the risk of developing orbital tumours in patients with retinoblastoma.
Professor Brian Mohney and his team, Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA, completed a non-comparative interventional case series on two patients who presented with bilateral retinoblastoma.
Subconjunctival chemotherapy was administered to both patients to reduce the risk or orbital tumour seeding after intravitreal injection. The outcome measures were ocular toxicity levels and the presence or absence of viable tumour cells at the injection site.
Subconjunctival chemotherapy bleb injections before intravitreal drug delivery seem to reduce the risk of orbital tumour seeding in patients with advanced stage retinoblastoma.
The paper was recently published in the British Journal of Ophthalmology and is available by clicking here.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
